AMP 2022
Nov 1–4, 2022

Phoenix, AZ | In-person

Join us at AMP and meet us in-person!

Paragon Genomics will be located at BOOTH #905 and hosting a corporate workshop at ROOM 226ABC titled:

Custom multiplex panels: From wastewater surveillance to pharmacogenomics (PGx) applications. Our distinguished panel discusses how they have utilized streamlined workflows to improve their research.

Edwin Oh, Associate Professor, Nevada Institute of Personalized Medicine, will be presenting utilization of WGS tools to define the emergence and evolution of actionable pathogens (i.e. SARS-CoV-2, Influenza, monkeypox, and polio) from clinical and wastewater samples. For SARS, he will share how WGS variant analysis from wastewater shows a 2-4 weeks lead time for the discovery of all Omicron sub-variants ahead of public health surveillance and share preliminary data of Oxford Nanopore Technology (ONT) compatibility with Paragon’s SARS-CoV-2 panel.

Matthew Beckman, Director of Laboratory Services, GENETWORx, will discuss the development and automation of NGS panels for personalized medicine in the mental health and medication space. He will discuss the need and testing of a comprehensive PGx panel that contains enough genes to cover the complexities of a mental health component and still maintains personalized coverage but can accomplish high throughput scale to adequately serve the population health aspects.

Edwin Oh on wastewater SARS-CoV-2 sequencing for COVID-19 surveillanceDr. Edwin Oh received his Ph.D. in Neuroscience from the University of Michigan at Ann Arbor. Following a postdoctoral fellowship at Johns Hopkins University, he served as an Assistant Professor in the Department of Neurology at Duke University. Dr. Oh is currently an Associate Professor in the UNLV School of Medicine. He is driven by a desire to understand how genetic and structural variants contribute to human health and disease and how we use this understanding to better diagnose genetic diseases and develop therapeutic programs for treatment. During the COVID-19 pandemic, the lab together with community partners such as the Southern Nevada Health District and the Southern Nevada Water Authority used molecular tools to study the spread of COVID-19 in Southern Nevada using wastewater and clinical samples. His lab is funded currently through grants from NIH and CDC.

Dr. Matthew Beckman is a co-founder and Director of Laboratory Services at GENETWORx in Glen Allen,
VA. He obtained his BA degree in Biology from Franciscan University, Steubenville, OH and received MS and PhD degrees in Nutritional Physiology at Iowa State University, Ames, IA. He worked as a
Postdoctoral Scientist at the University of Wisconsin for the next seven years in three additional labs and
then as a Professor at Virginia Commonwealth University for the ensuing 12 years. Since then, he ventured into commercial healthcare industry working at American International Biotechnology where he helped to develop the country’s first Pharmacogenetic Test on a Next Generation Sequencing platform. He joined his present company GENETWORx as their first employee in July of 2013, and served in multiple roles including Technical Supervisor, Lab Manager, and is the current Director of the lab team and directs the R&D Division. Dr. Beckman has developed and validated all the molecular tests offered at GENETWORx. In 2017, GENETWORx was purchased by Recovery Centers of America (RCA) and this aquisition led to significant growth in the GENETWORx test menu and expansion into Clinical Chemistry, Pharmacogenetic testing, and advancement in testing for infectious diseases. He was instrumental in putting GENETWORx on the national map as a major testing center for COVID-19 in 2020. Since March of 2020, GENETWORx performed nearly 12 million tests for COVID-19.

Contact us to schedule a time to meet and discuss your project needs or visit us at our booth or workshop to speak directly to our experts.